{"id":"938ed08f-eb36-40c6-99f0-d62f8456c3bd","kind":"companies","code":"UB-C3415","name":"Keyin Biotechnology","nameBasis":"transliterated","summary":"Developer of innovative drugs using AI.","description":"Keyin Biotech is an AI innovative drug developer.","country":"China","category":null,"originalName":"科因生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-03T00:00:00.000Z","englishUpdatedAt":"2026-10-15T20:25:35.659Z","reviewedAt":"2026-10-15T20:25:35.659Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"10d2f70939e3488b4047eaba114bf379444df92e98e3acadae8f9b15196128cf","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"AI创新药物研发商\n\n科因生物是一家AI创新药物研发商","sources":[],"related":[{"id":"c2d4b4e8-71ca-4236-8eb5-e635b2e8d3b6","kind":"products","code":"UB-D356","name":"Keyin Biotechnology","nameBasis":"transliterated","summary":"Keyin Biology develops innovative AI drugs. It rapidly built a first-principles de novo drug design platform that systematically explores chemical space and improves virtual discovery for new targets. By efficiently integrating upstream and downstream partners and coordinating internal and external R&D, it improves the DMTA cycle and reduces experimentation costs and timelines.","description":"Keyin Biology develops innovative AI drugs. It rapidly built a first-principles de novo drug design platform that systematically explores chemical space and improves virtual discovery for new targets. By efficiently integrating upstream and downstream partners and coordinating internal and external R&D, it improves the DMTA cycle and reduces experimentation costs and timelines.","country":null,"category":"Health management","originalName":"科因生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-11T18:07:15.125Z","englishUpdatedAt":"2026-10-15T22:47:27.842Z","reviewedAt":"2026-10-15T22:47:27.842Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"5d66c9350d907db64c6fed7d939ae450656b7ea64847881cf8629d5c343b188e","companyId":"938ed08f-eb36-40c6-99f0-d62f8456c3bd","foundedYear":null,"logoUrl":null,"path":"/products/keyinshengwu"},{"id":"54a80428-68df-4153-b3e2-406e76e40b27","kind":"news","code":"54a80428-68df-4153-b3e2-406e76e40b27","name":"Keyin Biotechnology completes strategic financing","nameBasis":"translated-title","summary":"","description":"","country":null,"category":null,"originalName":"科因生物完成战略投资融资","eventDate":"2022-12-20T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-15T22:00:24.014Z","englishUpdatedAt":"2026-10-16T01:39:38.719Z","reviewedAt":"2026-10-16T01:39:38.719Z","snapshotAt":"2026-10-16T01:38:14.029Z","sourceHash":"5d4bf76ff156d4c7589f534f07a27d461e0f5b51ee976b489921c2e8bdff387d","companyId":"938ed08f-eb36-40c6-99f0-d62f8456c3bd","foundedYear":null,"logoUrl":null,"path":"/news/54a80428-68df-4153-b3e2-406e76e40b27"},{"id":"22fbdc2e-14ee-463c-afbd-7b95a0de8332","kind":"institutions","code":"UB-I4479","name":"乾广旺利","nameBasis":"transliterated","summary":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","description":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"乾广旺利","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:27.175Z","englishUpdatedAt":"2026-10-15T18:43:03.537Z","reviewedAt":"2026-10-15T18:43:03.537Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1d577f4aaa1b80490b7e24008117fb469cda434255381ad46e2c2eb0467ed96f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Qianguangwangli","path":"/institutions/qianguangwangli"},{"id":"f21fb2b8-ee0c-4101-9214-2cbb7a8484e0","kind":"institutions","code":"UB-I4996","name":"函数资本","nameBasis":"transliterated","summary":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","description":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","country":null,"category":null,"originalName":"函数资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:34:23.416Z","englishUpdatedAt":"2026-10-15T18:26:25.229Z","reviewedAt":"2026-10-15T18:26:25.229Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1bad23e82612bc6e17b43493b8f4a88a4491a02bc02ddb9e094da2e9bd59b437","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Hanshu Capital","path":"/institutions/hanshu-capital"},{"id":"595aff71-62ae-4065-bd09-329ce818f7ba","kind":"institutions","code":"UB-I5007","name":"宜信","nameBasis":"transliterated","summary":"Financial technology company undertaking strategic investments.","description":"Financial technology company undertaking strategic investments.","country":null,"category":null,"originalName":"宜信","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:10:27.504Z","englishUpdatedAt":"2026-10-15T20:18:30.572Z","reviewedAt":"2026-10-15T20:18:30.572Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4aac8476d6ebd7bc01354016e7c76740a6d6ce2cca1e0b94c303e3d2847ab30f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Yixin","path":"/institutions/yixin"},{"id":"6a4330f3-6610-46dd-9376-8b7fc20c31d0","kind":"institutions","code":"UB-I190","name":"峰瑞资本","nameBasis":"transliterated","summary":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","description":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","country":null,"category":null,"originalName":"峰瑞资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:54:24.732Z","englishUpdatedAt":"2026-10-15T21:15:05.801Z","reviewedAt":"2026-10-15T21:15:05.801Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"9c4cb8aa548efade3157323554b79d34461258e0af2392b2a59f97aa9ff1c8c6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Fengrui Capital","path":"/institutions/fengrui-capital"}],"finance":{"funding":{"metric":"funding","count":1,"latest":null,"years":[],"points":[],"linePoints":[],"conflictGroups":0,"omittedRecordCount":1,"records":[{"id":"54a80428-68df-4153-b3e2-406e76e40b27","date":"2022-12-20T00:00:00.000Z","round":"Strategic","amountText":"未披露","estimateUsd":null,"estimateLabel":"Undisclosed","estimateNote":null,"investors":"峰瑞资本,函数资本,乾广旺利,宜信","institutions":[{"id":"22fbdc2e-14ee-463c-afbd-7b95a0de8332","kind":"institutions","code":"UB-I4479","name":"乾广旺利","nameBasis":"transliterated","summary":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","description":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"乾广旺利","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:27.175Z","englishUpdatedAt":"2026-10-15T18:43:03.537Z","reviewedAt":"2026-10-15T18:43:03.537Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1d577f4aaa1b80490b7e24008117fb469cda434255381ad46e2c2eb0467ed96f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Qianguangwangli","path":"/institutions/qianguangwangli"},{"id":"f21fb2b8-ee0c-4101-9214-2cbb7a8484e0","kind":"institutions","code":"UB-I4996","name":"函数资本","nameBasis":"transliterated","summary":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","description":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","country":null,"category":null,"originalName":"函数资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:34:23.416Z","englishUpdatedAt":"2026-10-15T18:26:25.229Z","reviewedAt":"2026-10-15T18:26:25.229Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1bad23e82612bc6e17b43493b8f4a88a4491a02bc02ddb9e094da2e9bd59b437","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Hanshu Capital","path":"/institutions/hanshu-capital"},{"id":"595aff71-62ae-4065-bd09-329ce818f7ba","kind":"institutions","code":"UB-I5007","name":"宜信","nameBasis":"transliterated","summary":"Financial technology company undertaking strategic investments.","description":"Financial technology company undertaking strategic investments.","country":null,"category":null,"originalName":"宜信","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:10:27.504Z","englishUpdatedAt":"2026-10-15T20:18:30.572Z","reviewedAt":"2026-10-15T20:18:30.572Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4aac8476d6ebd7bc01354016e7c76740a6d6ce2cca1e0b94c303e3d2847ab30f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Yixin","path":"/institutions/yixin"},{"id":"6a4330f3-6610-46dd-9376-8b7fc20c31d0","kind":"institutions","code":"UB-I190","name":"峰瑞资本","nameBasis":"transliterated","summary":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","description":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","country":null,"category":null,"originalName":"峰瑞资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:54:24.732Z","englishUpdatedAt":"2026-10-15T21:15:05.801Z","reviewedAt":"2026-10-15T21:15:05.801Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"9c4cb8aa548efade3157323554b79d34461258e0af2392b2a59f97aa9ff1c8c6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Fengrui Capital","path":"/institutions/fengrui-capital"}],"newsUrl":null,"evidence":{"headline":"Keyin Biotechnology completes strategic financing","brief":null,"basis":null,"newsPath":"/news/54a80428-68df-4153-b3e2-406e76e40b27","sourceCount":0}}],"totalRaised":null},"valuation":{"metric":"valuation","count":1,"latest":null,"years":[],"points":[],"linePoints":[],"conflictGroups":0,"omittedRecordCount":1,"records":[{"id":"54a80428-68df-4153-b3e2-406e76e40b27","date":"2022-12-20T00:00:00.000Z","round":"Strategic","amountText":null,"estimateUsd":null,"estimateLabel":null,"estimateNote":null,"investors":"峰瑞资本,函数资本,乾广旺利,宜信","institutions":[{"id":"22fbdc2e-14ee-463c-afbd-7b95a0de8332","kind":"institutions","code":"UB-I4479","name":"乾广旺利","nameBasis":"transliterated","summary":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","description":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"乾广旺利","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:27.175Z","englishUpdatedAt":"2026-10-15T18:43:03.537Z","reviewedAt":"2026-10-15T18:43:03.537Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1d577f4aaa1b80490b7e24008117fb469cda434255381ad46e2c2eb0467ed96f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Qianguangwangli","path":"/institutions/qianguangwangli"},{"id":"f21fb2b8-ee0c-4101-9214-2cbb7a8484e0","kind":"institutions","code":"UB-I4996","name":"函数资本","nameBasis":"transliterated","summary":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","description":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","country":null,"category":null,"originalName":"函数资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:34:23.416Z","englishUpdatedAt":"2026-10-15T18:26:25.229Z","reviewedAt":"2026-10-15T18:26:25.229Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1bad23e82612bc6e17b43493b8f4a88a4491a02bc02ddb9e094da2e9bd59b437","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Hanshu Capital","path":"/institutions/hanshu-capital"},{"id":"595aff71-62ae-4065-bd09-329ce818f7ba","kind":"institutions","code":"UB-I5007","name":"宜信","nameBasis":"transliterated","summary":"Financial technology company undertaking strategic investments.","description":"Financial technology company undertaking strategic investments.","country":null,"category":null,"originalName":"宜信","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:10:27.504Z","englishUpdatedAt":"2026-10-15T20:18:30.572Z","reviewedAt":"2026-10-15T20:18:30.572Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4aac8476d6ebd7bc01354016e7c76740a6d6ce2cca1e0b94c303e3d2847ab30f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Yixin","path":"/institutions/yixin"},{"id":"6a4330f3-6610-46dd-9376-8b7fc20c31d0","kind":"institutions","code":"UB-I190","name":"峰瑞资本","nameBasis":"transliterated","summary":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","description":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","country":null,"category":null,"originalName":"峰瑞资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:54:24.732Z","englishUpdatedAt":"2026-10-15T21:15:05.801Z","reviewedAt":"2026-10-15T21:15:05.801Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"9c4cb8aa548efade3157323554b79d34461258e0af2392b2a59f97aa9ff1c8c6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Fengrui Capital","path":"/institutions/fengrui-capital"}],"newsUrl":null,"evidence":{"headline":"Keyin Biotechnology completes strategic financing","brief":null,"basis":null,"newsPath":"/news/54a80428-68df-4153-b3e2-406e76e40b27","sourceCount":0}}]},"revenue":{"metric":"revenue","count":0,"latest":null,"years":[],"points":[],"linePoints":[],"conflictGroups":0,"omittedRecordCount":0,"records":[]}},"events":[{"id":"54a80428-68df-4153-b3e2-406e76e40b27","kind":"funding","eventDate":"2022-12-20T00:00:00.000Z","revenueDate":null,"round":"战略投资","amountText":"未披露","valuationText":null,"revenueText":"","cumulativeFundingText":"","amountEstimateUsd":null,"valuationEstimateUsd":null,"revenueEstimateUsd":null,"cumulativeFundingEstimateUsd":null,"investors":"峰瑞资本,函数资本,乾广旺利,宜信","newsUrl":null,"newsTypes":["融资"],"institutions":[{"id":"22fbdc2e-14ee-463c-afbd-7b95a0de8332","kind":"institutions","code":"UB-I4479","name":"乾广旺利","nameBasis":"transliterated","summary":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","description":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"乾广旺利","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:27.175Z","englishUpdatedAt":"2026-10-15T18:43:03.537Z","reviewedAt":"2026-10-15T18:43:03.537Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1d577f4aaa1b80490b7e24008117fb469cda434255381ad46e2c2eb0467ed96f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Qianguangwangli","path":"/institutions/qianguangwangli"},{"id":"f21fb2b8-ee0c-4101-9214-2cbb7a8484e0","kind":"institutions","code":"UB-I4996","name":"函数资本","nameBasis":"transliterated","summary":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","description":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","country":null,"category":null,"originalName":"函数资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:34:23.416Z","englishUpdatedAt":"2026-10-15T18:26:25.229Z","reviewedAt":"2026-10-15T18:26:25.229Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1bad23e82612bc6e17b43493b8f4a88a4491a02bc02ddb9e094da2e9bd59b437","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Hanshu Capital","path":"/institutions/hanshu-capital"},{"id":"595aff71-62ae-4065-bd09-329ce818f7ba","kind":"institutions","code":"UB-I5007","name":"宜信","nameBasis":"transliterated","summary":"Financial technology company undertaking strategic investments.","description":"Financial technology company undertaking strategic investments.","country":null,"category":null,"originalName":"宜信","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:10:27.504Z","englishUpdatedAt":"2026-10-15T20:18:30.572Z","reviewedAt":"2026-10-15T20:18:30.572Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4aac8476d6ebd7bc01354016e7c76740a6d6ce2cca1e0b94c303e3d2847ab30f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Yixin","path":"/institutions/yixin"},{"id":"6a4330f3-6610-46dd-9376-8b7fc20c31d0","kind":"institutions","code":"UB-I190","name":"峰瑞资本","nameBasis":"transliterated","summary":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","description":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","country":null,"category":null,"originalName":"峰瑞资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:54:24.732Z","englishUpdatedAt":"2026-10-15T21:15:05.801Z","reviewedAt":"2026-10-15T21:15:05.801Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"9c4cb8aa548efade3157323554b79d34461258e0af2392b2a59f97aa9ff1c8c6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Fengrui Capital","path":"/institutions/fengrui-capital"}],"roundName":"Strategic","amountLabel":"Undisclosed","valuationLabel":null,"revenueLabel":null,"cumulativeFundingLabel":null}],"team":[],"productsRelated":[{"id":"c2d4b4e8-71ca-4236-8eb5-e635b2e8d3b6","kind":"products","code":"UB-D356","name":"Keyin Biotechnology","nameBasis":"transliterated","summary":"Keyin Biology develops innovative AI drugs. It rapidly built a first-principles de novo drug design platform that systematically explores chemical space and improves virtual discovery for new targets. By efficiently integrating upstream and downstream partners and coordinating internal and external R&D, it improves the DMTA cycle and reduces experimentation costs and timelines.","description":"Keyin Biology develops innovative AI drugs. It rapidly built a first-principles de novo drug design platform that systematically explores chemical space and improves virtual discovery for new targets. By efficiently integrating upstream and downstream partners and coordinating internal and external R&D, it improves the DMTA cycle and reduces experimentation costs and timelines.","country":null,"category":"Health management","originalName":"科因生物","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-11T18:07:15.125Z","englishUpdatedAt":"2026-10-15T22:47:27.842Z","reviewedAt":"2026-10-15T22:47:27.842Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"5d66c9350d907db64c6fed7d939ae450656b7ea64847881cf8629d5c343b188e","companyId":"938ed08f-eb36-40c6-99f0-d62f8456c3bd","foundedYear":null,"logoUrl":null,"path":"/products/keyinshengwu"}],"investors":[{"id":"22fbdc2e-14ee-463c-afbd-7b95a0de8332","kind":"institutions","code":"UB-I4479","name":"乾广旺利","nameBasis":"transliterated","summary":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","description":"Qianguangwangli is a Chinese private equity firm, specializing in equity investment in growth-stage and mature unlisted companies.","country":null,"category":null,"originalName":"乾广旺利","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:46:27.175Z","englishUpdatedAt":"2026-10-15T18:43:03.537Z","reviewedAt":"2026-10-15T18:43:03.537Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1d577f4aaa1b80490b7e24008117fb469cda434255381ad46e2c2eb0467ed96f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Qianguangwangli","path":"/institutions/qianguangwangli"},{"id":"f21fb2b8-ee0c-4101-9214-2cbb7a8484e0","kind":"institutions","code":"UB-I4996","name":"函数资本","nameBasis":"transliterated","summary":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","description":"Hanshu Capital is a domestic venture capital firm, focused on equity investment in seed- to startup-stage ventures.","country":null,"category":null,"originalName":"函数资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:34:23.416Z","englishUpdatedAt":"2026-10-15T18:26:25.229Z","reviewedAt":"2026-10-15T18:26:25.229Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"1bad23e82612bc6e17b43493b8f4a88a4491a02bc02ddb9e094da2e9bd59b437","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Hanshu Capital","path":"/institutions/hanshu-capital"},{"id":"595aff71-62ae-4065-bd09-329ce818f7ba","kind":"institutions","code":"UB-I5007","name":"宜信","nameBasis":"transliterated","summary":"Financial technology company undertaking strategic investments.","description":"Financial technology company undertaking strategic investments.","country":null,"category":null,"originalName":"宜信","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:10:27.504Z","englishUpdatedAt":"2026-10-15T20:18:30.572Z","reviewedAt":"2026-10-15T20:18:30.572Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"4aac8476d6ebd7bc01354016e7c76740a6d6ce2cca1e0b94c303e3d2847ab30f","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Yixin","path":"/institutions/yixin"},{"id":"6a4330f3-6610-46dd-9376-8b7fc20c31d0","kind":"institutions","code":"UB-I190","name":"峰瑞资本","nameBasis":"transliterated","summary":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","description":"A Chinese venture capital firm focused on early-stage technology and healthcare investments.","country":null,"category":null,"originalName":"峰瑞资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:54:24.732Z","englishUpdatedAt":"2026-10-15T21:15:05.801Z","reviewedAt":"2026-10-15T21:15:05.801Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"9c4cb8aa548efade3157323554b79d34461258e0af2392b2a59f97aa9ff1c8c6","companyId":null,"foundedYear":null,"logoUrl":null,"nameLang":"zh","transliteratedName":"Fengrui Capital","path":"/institutions/fengrui-capital"}],"path":"/companies/keyinshengwu","structured":{"city":"Shanghai","country":"China","location":null,"role":null,"category":null,"company":null},"definition":"Keyin Biotechnology is a company in the Industry apps sector headquartered in Shanghai, China.","summaryBasis":"translated","thin":false,"canonical":"https://uniquebase.ai/companies/keyinshengwu"}